Predictors of long-term opioid treatmentamongpatientswho receive chemoradiation for head and neck cancer

Oncologist

Volumn 18, Issue 6, 2013, Pages 768-774

  Kwon, Jung Hye ^a,b   Hui, David ^b   Chisholm, Gary ^c   Bruera, Eduardo ^b  

^a Hallym University   (South Korea)

^b Department of Palliative Care and Rehabilitation Medicine ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CAGE; Head and neck cancer; Opioids; Radiation; Treatment related side effects

Indexed keywords

DEXTROPROPOXYPHENE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; TRAMADOL;

ADULT; ALCOHOLISM; ARTICLE; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CONSULTATION; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION DOSE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM;

CAGE; HEAD AND NECK CANCER; OPIOIDS; RADIATION; TREATMENT-RELATED SIDE EFFECTS;

ANALGESICS, OPIOID; CHEMORADIOTHERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM STAGING; OPIOID-RELATED DISORDERS; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 84879485458     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0001     Document Type: Article

References (45)

1. Seiwert TY, Salama JK, Vokes EE. The chemora-diation paradigm in head and neckcancer. Nat Clin Pract Oncol 2008;4:156-171.
2. Trotti A, Bellm Lam, Epstein JB et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with orwithoutchemotherapy:Asys-tematic literature review. Radiother Oncol 2003; 66:253-262.
3. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007; 68:654-661.
4. Robertson C, Robertson AG, Hendry JH et al. Similar decreases in local tumor control are calcu lated for treatment protraction and for interruptions in the radiotherapy of carcinoma ofthe larynx in fourcenters. Int J Radiat Oncol Biol Phys 1998;40: 319-329.
5. Zenda S, Matsuura K, Tachibana H et al. Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy. Radiother Oncol 2011;101:410-414.
6. Bensadoun RJ, Franquin JC, Ciais G et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 1999;7: 244-252.
7. Chen SC, Lai YH, Liao CTet al. Changes of symptoms and depression in oral cavity cancer patients receiving radiation therapy. Oral Oncol 2010;46: 509-513.
8. Epstein JB, Hong C, Logan RM. et al. Asystem-atic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer 2010;18: 1023-1031.
9. List MA, Siston A, Haraf D et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: A prospective examination. J Clin Oncol 1999;17:1020-1028.
10. Epstein JB, Elad S, Eliav E et al. Orofacial pain in cancer: Part II-Clinical perspectives and management. J Dent Res 2007;86:506-518.
11. Fischer DJ, Klasser GD, Epstein JB. Cancer and orofacial pain. Oral Maxillofac Surg Clin North Am 2008;20:287-301.
12. Larance B, Degenhardt L, Lintzeris N et al. Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev 2011;30:236-245.
13. Passik SD, Kirsh KL, McDonald MVet al. Apilot surveyofaberrantdrug-takingattitudesand behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage 2000;19:274-286.
14. Boscarino JA, Rukstalis M, Hoffman SN et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 2010;105:1776-1782.
15. Edlund MJ, Steffick D, Hudson Tet al. Riskfac-tors for clinically recognized opioid abuse and de-pendenceamong veteransusingopioidsforchronic non-cancerpain. Pain 2007;129:355-362.
16. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22:173-181.
17. Passik SD, Schreiber J, Kirsh KL, Portenoy RK. A chart reviewofthe ordering and documentation of urine toxicologyscreens in a cancercenter: Do they influence patient management? J Pain Symptom Manage 2000;19:40-44.
18. Lawlor P, Walker P, Bruera Eet al. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 1997;13:356-361.
19. Parsons HA, Delgado-Guay MO, El Osta Bet al. Alcoholism screening in patients with advanced cancer: Impacton symptom burden and opioid use. J Palliat Med 2008;11:964-968.
20. Dev R, Parsons HA, Palla S et al. Undocumented alcoholism and its correlation with tobacco and illegal drug use in advanced cancer patients. Cancer 2011;117:4551-4556.
21. Kwon JH, Hui D, Chisholm Get al. Clinical characteristics of cancer patients referred early to supportive and palliative care. J Palliat Med 2013;16: 148-155.
22. Ackerstaff AH, Tan IB, Rasch CRet al. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2002;128:1185-1190.
23. van der Molen L, van Rossum MA, Burkhead LM et al. A randomized preventive rehabilitation trial in advanced head and neck cancer patients treated with chemoradiotherapy: Feasibility, compliance, and short-term effects. Dysphagia 2011; 26:155-170.
24. Boscolo-Rizzo P, Maronato F, Marchiori C et al. Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope 2008;118:300-306.
25. Moore AA, Seeman T, Morgenstern H et al. Are there differences between older persons who screen positive on the CAGE questionnaire and the Short Michigan Alcoholism Screening Test-Geriatric Version?JAm Geriatr Soc 2002;50:858-862.
26. Ewing JA. Detecting alcoholism: The CAGE questionnaire. JAMA 1984;252:1905-1907.
27. Bisson J, Nadeau L, Demers A. The validity of the CAGE scale to screen for heavy drinking and drinking problems in a general population survey. Addiction 1999;94:715-722.
28. Bruera E, Kuehn N, Miller MJ et al. The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.
29. Cummings G, Biondo PD, Campbell D et al. Can the global uptake of palliative care innovations be improved? Insights from a bibliometric analysis of the Edmonton Symptom Assessment System. Pal-liat Med 2011;25:71-82.
30. McPherson ML. Demystifying opioid conversion calculations: A guide for effective dosing. Bethesda, MD: American Society of Health-System Pharmacists, 2009:5.
31. Hallenbeck JL. Palliative care perspectives. New York: Oxford University Press, 2003:71.
32. Mercadante S, Caraceni A. Conversion ratios foropioid switching in the treatmentofcancerpain: Asystematic review. Palliat Med 2011;25:504-515.
33. Bruera E, Moyano J, Seifert L et al. The fre-quencyofalcoholismamong patients with pain due to terminal cancer. J Pain Symptom Manage 1995; 10:599-603.
34. Epstein JB, Thariat J, Bensadoun RJ et al. Oral complications of cancer and cancer therapy: From cancer treatment to survivorship. CA Cancer J Clin 2012;62:400-422.
35. Anantharaman D, Marron M, Lagiou P et al. Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer. Oral Oncol 2011;47:725-731.
36. Oswald LM, Wand GS. Opioidsandalcoholism. Physiol Behav2004;81:339-358.
37. McLellan AT, Lewis DC, O'Brien CP et al. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA2000;284:1689-1695.
38. Koob GF. Dynamics of neuronal circuits in addiction: Reward, antireward, and emotional memory. Pharmacopsychiatry 2009;42:S32-S41.
39. Lobmaier PP, Kunøe N, Gossop M et al. Naltrexone depot formulations for opioid and alcohol dependence: A systematic review. CNS Neurosci Ther2011;17:629-636.
40. Stinson FS, Grant BF, Dawson DA et al. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2005;80: 105-116.
41. Starr TD, Rogak LJ, Passik SD. Substanceabuse in cancer pain. Curr Pain Headache Rep 2010;14: 268-275.
42. Derogatis LR, Morrow GR, Fetting J et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983;249:751-757.
43. U.S. Department of Health and Human Services. Results from the 2010 National Survey on Drug Use and Health: Summaryofnational findings. Available at http://www.samhsa.gov/data/nsduh/ 2k10nsduh/2k10results.htm. Accessed November 27, 2012.
44. Sullivan MD, Edlund MJ, Fan MY et al. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: The TROUP Study. Pain 201;150:332-339.
45. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: A systematic review and literature synthesis. Clin J Pain 2008;24:497-508.